Postmenopausal hormone replacement therapy and plasma lipoproteins.
Taskinen
M R
MR
D000368:Aged; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000008:administration & dosage / Q000097:blood; D004311:Double-Blind Method; D004338:Drug Combinations; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D017258:Medroxyprogesterone Acetate / Q000097:blood; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009640:Norethindrone / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077563:Norethindrone Acetate; D009644:Norgestrel / Q000627:therapeutic use; D017698:Postmenopause; D045167:Progesterone Congeners / Q000627:therapeutic use; D011372:Progestins / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D008076:Cholesterol, HDL; D004338:Drug Combinations; D004967:Estrogens; D008074:Lipoproteins; D045167:Progesterone Congeners; D011372:Progestins; D009644:Norgestrel; D000077563:Norethindrone Acetate; D017258:Medroxyprogesterone Acetate; D009640:Norethindrone